Valion Bio, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Melinda Lackey, General Counsel and SVP of Legal Affairs, separated from Valion Bio effective October 30, 2026, after 6 months of employment (hired May 1, 2026). Valion paid $26,750 gross severance plus COBRA premiums through November 30, 2026, in exchange for a broad release of all claims. Concurrently, the company announced positive safety results for lead drug Entolimod and that NIAID/AFRRI will fund a therapeutic efficacy study with top-line results expected December 2026.
Why this rating
Departure of counsel is routine; $26.75K is ~0.7% of $4M market cap. Drug milestone (positive news) separate from severance and offset by loss of legal leadership mid-development.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.